TW202233676A - 使用抗ｃｄ１９抗體治療自體免疫性疾病 - Google Patents

使用抗ｃｄ１９抗體治療自體免疫性疾病 Download PDF

Info

Publication number
TW202233676A
TW202233676A TW110140391A TW110140391A TW202233676A TW 202233676 A TW202233676 A TW 202233676A TW 110140391 A TW110140391 A TW 110140391A TW 110140391 A TW110140391 A TW 110140391A TW 202233676 A TW202233676 A TW 202233676A
Authority
TW
Taiwan
Prior art keywords
patient
nmosd
antibody
vib551
treatment
Prior art date
Application number
TW110140391A
Other languages
English (en)
Chinese (zh)
Inventor
德偉 佘
傑克 瑞奇福德
埃利澤 卡茨
威廉 雷斯
Original Assignee
美商維埃拉生物股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商維埃拉生物股份有限公司 filed Critical 美商維埃拉生物股份有限公司
Publication of TW202233676A publication Critical patent/TW202233676A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW110140391A 2020-10-29 2021-10-29 使用抗ｃｄ１９抗體治療自體免疫性疾病 TW202233676A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202063107182P 2020-10-29 2020-10-29
US63/107,182 2020-10-29
US202163143541P 2021-01-29 2021-01-29
US63/143,541 2021-01-29
US202163178286P 2021-04-22 2021-04-22
US63/178,286 2021-04-22

Publications (1)

Publication Number Publication Date
TW202233676A true TW202233676A (zh) 2022-09-01

Family

ID=81384348

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110140391A TW202233676A (zh) 2020-10-29 2021-10-29 使用抗ｃｄ１９抗體治療自體免疫性疾病

Country Status (10)

Country Link
US (1) US20230287114A1 (https=)
EP (1) EP4237447A4 (https=)
JP (1) JP2023549075A (https=)
KR (1) KR20230097118A (https=)
AU (1) AU2021368769A1 (https=)
CA (1) CA3197022A1 (https=)
IL (1) IL302294A (https=)
MX (1) MX2023004794A (https=)
TW (1) TW202233676A (https=)
WO (1) WO2022094334A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023534916A (ja) * 2020-06-30 2023-08-15 ビエラ バイオ インコーポレイテッド 視神経脊髄炎スペクトラム障害を治療する方法
WO2025202213A1 (en) 2024-03-26 2025-10-02 Institut National de la Santé et de la Recherche Médicale Lipid nanoparticle loaded with antitumoral agent and functionnalized to target immosuppressive cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201401465D0 (en) * 2014-01-29 2014-03-12 Roach Arthur H Use of cladribine for treating autoimmune inflammatory disease
MX2021012870A (es) * 2019-04-24 2022-01-18 Viela Bio Inc Uso de un anticuerpo anti cúmulo de diferenciación 19 (cd19) para tratar enfermedades autoinmunitarias.
JP2023534916A (ja) * 2020-06-30 2023-08-15 ビエラ バイオ インコーポレイテッド 視神経脊髄炎スペクトラム障害を治療する方法

Also Published As

Publication number Publication date
EP4237447A1 (en) 2023-09-06
KR20230097118A (ko) 2023-06-30
IL302294A (en) 2023-06-01
EP4237447A4 (en) 2024-07-17
WO2022094334A1 (en) 2022-05-05
JP2023549075A (ja) 2023-11-22
AU2021368769A9 (en) 2024-05-30
MX2023004794A (es) 2023-09-15
CA3197022A1 (en) 2022-05-05
US20230287114A1 (en) 2023-09-14
AU2021368769A1 (en) 2023-06-08

Similar Documents

Publication Publication Date Title
Collongues et al. Pharmacotherapy for neuromyelitis optica spectrum disorders: current management and future options
WO2023140269A1 (en) Treatment of autoimmune encephalitis with satralizumab
CA2490186C (en) Method for the treatment of multiple sclerosis
KR20240107372A (ko) 사트랄리주맙을 사용하는 중추 신경계(cns)의 탈수초화 질환의 치료
KR20220004113A (ko) 자가면역 질환을 치료하기 위한 항-cd19 항체의 용도
CA2973266A1 (en) Lingo-1 antagonists and uses for treatment of demyelinating disorders
EP3864053B1 (en) Treatment of rms by switching therapy
US20230287114A1 (en) Use of an anti-cd19 antibody to treat autoimmune disease
Valencia-Sanchez et al. Emerging Targeted Therapies for Neuromyelitis Optica Spectrum Disorders: C. Valencia-Sanchez et al.
JP2022501378A (ja) 視神経脊髄炎の処置のためのエクリズマブ
CN116322765A (zh) 用于用奥瑞珠单抗治疗多发性硬化症的方法
US20240270842A1 (en) Use of an anti-cd19 antibody to treat myasthenia gravis
HK40096777A (zh) 使用抗cd19抗体治疗自身免疫性疾病
CN116583538A (zh) 使用抗cd19抗体治疗自身免疫性疾病
JP2023504209A (ja) 視神経脊髄炎スペクトラム障害の治療のための抗ｃ５抗体
EA052907B1 (ru) Применение антитела к cd19 для лечения миастении гравис
CN117440827A (zh) 使用抗cd19抗体治疗重症肌无力
Wiśniewska et al. Exploring treatment approaches for Neuromyelitis Optica Spectrum Disorders (NMOSD)
Moretz Drug Class Review with New Drug Evaluation: Biologics for Autoimmune Disorders-Neuromyelitis Optica Spectrum Disorder
HK40051003A (en) Treatment of rms by switching therapy
HK40051003B (en) Treatment of rms by switching therapy
Li et al. Optic Neuritis in the Era of MOGAD and NMOSD: Redefining the Atypical